| Bioactivity | TA-316 GMP (Megakaryocytes/platelets inducing agent GMP) is a chemically synthesized c-MPL (thrombopoietin receptor) agonist (CMA). TA-316 GMP promotes platelet production, and its activity is comparable to that of recombinant human thrombopoietin (rhTPO) in some respects. TA-316 GMP acts by binding to the c-MPL receptor, activating related signaling pathways such as JAK/STAT, MAPK, and PI3K/AKT, which are critical for the proliferation and maturation of megakaryocytes (MKs, platelet precursors). TA-316 GMP also specifically upregulates the expression of vascular endothelial growth factor A (VEGFA) and fibroblast growth factor 2 (FGF2) both of which are associated with megakaryocyte maturation and platelet production. TA-316 GMP can be used in the study of platelet amplification[1]. |
| CAS | 1429321-13-0 |
| Formula | C28H25BrN4O5S2 |
| Molar Mass | 641.56 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Aihara A, et al. Novel TPO receptor agonist TA-316 contributes to platelet biogenesis from human iPS cells[J]. Blood advances, 2017, 1(7): 468-476. |
TA-316 (GMP)
CAS: 1429321-13-0 F: C28H25BrN4O5S2 W: 641.56
TA-316 GMP (Megakaryocytes/platelets inducing agent GMP) is a chemically synthesized c-MPL (thrombopoietin receptor) ago
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.